Limits...
Oncogenic osteomalacia illustrating the effect of fibroblast growth factor 23 on phosphate homeostasis.

Westerberg PA, Linde T, Vanderschueren D, Billen J, Jans I, Ljunggren Ö - Clin Kidney J (2012)

Bottom Line: In oncogenic osteomalacia (OOM), fibroblast growth factor 23 (FGF23) induces renal phosphate wasting and inhibits the appropriate increase of calcitriol.Serum calcium, phosphate, biointact parathyroid hormone and intact FGF23 as well as the calcitriol and 24,25-vitamin D levels were measured before and after tumour removal.The clinical approach to a patient with hypophosphataemia is discussed and the changes in mineral metabolism after removal of a FGF23-producing tumour are described.

View Article: PubMed Central - PubMed

Affiliation: Department of Medical Sciences, Uppsala University, Uppsala, Sweden.

ABSTRACT
In oncogenic osteomalacia (OOM), fibroblast growth factor 23 (FGF23) induces renal phosphate wasting and inhibits the appropriate increase of calcitriol. A patient suffering from OOM is described. Serum calcium, phosphate, biointact parathyroid hormone and intact FGF23 as well as the calcitriol and 24,25-vitamin D levels were measured before and after tumour removal. The clinical approach to a patient with hypophosphataemia is discussed and the changes in mineral metabolism after removal of a FGF23-producing tumour are described.

No MeSH data available.


Related in: MedlinePlus

Parameters of mineral metabolism before and after removal of an FGF23-producing tumour. Area between horizontal grey lines represent normal range.
© Copyright Policy - creative-commons
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4400509&req=5

fig1: Parameters of mineral metabolism before and after removal of an FGF23-producing tumour. Area between horizontal grey lines represent normal range.

Mentions: Immunoabsorbent assays were used for analyses of bioactive 1-84 PTH (Scantibodies) and intact FGF23 (Kainos; Japan) before extirpation and at 10 time points the first day, as well as after 1 and 2 weeks and 6 months, (see Table 1 and Figure 1). Serum calcitriol and 24,25-vitamin D were measured using liquid chromatography-tandem mass spectrometry recently described [6]. Serum was collected, protected from light and stored in −70°C until analysed.


Oncogenic osteomalacia illustrating the effect of fibroblast growth factor 23 on phosphate homeostasis.

Westerberg PA, Linde T, Vanderschueren D, Billen J, Jans I, Ljunggren Ö - Clin Kidney J (2012)

Parameters of mineral metabolism before and after removal of an FGF23-producing tumour. Area between horizontal grey lines represent normal range.
© Copyright Policy - creative-commons
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4400509&req=5

fig1: Parameters of mineral metabolism before and after removal of an FGF23-producing tumour. Area between horizontal grey lines represent normal range.
Mentions: Immunoabsorbent assays were used for analyses of bioactive 1-84 PTH (Scantibodies) and intact FGF23 (Kainos; Japan) before extirpation and at 10 time points the first day, as well as after 1 and 2 weeks and 6 months, (see Table 1 and Figure 1). Serum calcitriol and 24,25-vitamin D were measured using liquid chromatography-tandem mass spectrometry recently described [6]. Serum was collected, protected from light and stored in −70°C until analysed.

Bottom Line: In oncogenic osteomalacia (OOM), fibroblast growth factor 23 (FGF23) induces renal phosphate wasting and inhibits the appropriate increase of calcitriol.Serum calcium, phosphate, biointact parathyroid hormone and intact FGF23 as well as the calcitriol and 24,25-vitamin D levels were measured before and after tumour removal.The clinical approach to a patient with hypophosphataemia is discussed and the changes in mineral metabolism after removal of a FGF23-producing tumour are described.

View Article: PubMed Central - PubMed

Affiliation: Department of Medical Sciences, Uppsala University, Uppsala, Sweden.

ABSTRACT
In oncogenic osteomalacia (OOM), fibroblast growth factor 23 (FGF23) induces renal phosphate wasting and inhibits the appropriate increase of calcitriol. A patient suffering from OOM is described. Serum calcium, phosphate, biointact parathyroid hormone and intact FGF23 as well as the calcitriol and 24,25-vitamin D levels were measured before and after tumour removal. The clinical approach to a patient with hypophosphataemia is discussed and the changes in mineral metabolism after removal of a FGF23-producing tumour are described.

No MeSH data available.


Related in: MedlinePlus